期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

人类表皮生长因子受体2阳性乳腺癌患者曲妥珠单抗治疗前后生物标志物变化研究

暂未订购
导出
摘要 目的 探讨曲妥珠单抗在人类表皮生长因子受体2(human epidermal growth factor receptor 2,HER2)阳性乳腺癌患者治疗中的效果,并观察治疗前后生物标志物水平的变化。方法 选取2023年1—12月景德镇市第三人民医院收治的30例HER2阳性乳腺癌患者作为研究对象,采用随机数字表法将患者分为对照组和治疗组,各15例。对照组接受常规化疗,治疗组接受曲妥珠单抗联合常规化疗,检测2组患者治疗前后血清HER2蛋白、癌胚抗原(carcino embryonic antigen,CEA)和糖类抗原15-3(carbohydrate antigen 153,CA15-3)水平,并评估临床疗效及生存质量。结果 治疗后,治疗组HER2蛋白、CEA、CA15-3水平低于对照组(P<0.05)。治疗组客观缓解率(objective response rate,ORR)为80.0%,疾病控制率(disease control rate,DCR)为93.3%,显著高于对照组的33.3%和66.7%(P<0.05)。治疗后,治疗组欧洲癌症研究与治疗组织生活质量问卷(European organization for research and treatment of cancer quality of life questionnaire,EORTC QLQ-C30)中生理功能、心理状态、社会功能方面的评分均显著高于对照组(P<0.05)。结论 曲妥珠单抗联合常规化疗在HER2阳性乳腺癌患者中表现出显著的治疗效果,能够有效降低生物标志物水平,提高临床疗效和患者生存质量。
作者 吴玉玲
机构地区 景德镇市第三人民医院
出处 《基层医学论坛》 2025年第27期65-67,共3页
关键词 HER2阳性乳腺癌 曲妥珠单抗 生物标志物
分类号 R713.42 [医药卫生—妇产科学]
  • 相关文献

参考文献9

二级参考文献91

  • 1Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast can-cer[J]. N Engl J Med, 2006, 354(8):809-820.
  • 2Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastu-zumab after adjuvant chemotherapy in HER2-positive breast can-cer[J]. N Engl J Med, 2005, 353(16):1659-1672.
  • 3Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer[J]. N Engl J Med, 2005, 353(16):1673-1684.
  • 4Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2[J]. N Engl J Med, 2001, 344(11):783-792.
  • 5Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-over-expressing metastatic breast cancer[J]. J Clin Oncol, 2002, 20(3):719-726.
  • 6Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-pos-itive operable breast cancer[J]. J Clin Oncol, 2005, 23(16):3676-3685.
  • 7Buzdar AU, Valero V, Ibrahim NK, et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclo-phosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of ad-ditional patients treated with the same regimen[J]. Clin Cancer Res, 2007, 13(1):228-233.
  • 8Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemo-therapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised con-trolled superiority trial with a parallel HER2-negative cohort[J]. Lancet, 2010, 375(9712):377-384.
  • 9Untch M, Rezai M, Loibl S, et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the Ge-parQuattro study[J]. J Clin Oncol, 2010, 28(12):2024-2031.
  • 10Untch M, Loibl S, Bischoff J, et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemo-therapy (GeparQuinto, GBG 44): a randomised phase 3 trial[J]. Lancet Oncol, 2012, 13(2):135-144.

共引文献240

基层医学论坛
2025年 第27期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部